Trending Topic

3d rendered illustration - bladder
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Hyponatraemia is primarily a disorder of water balance or distribution, characterized by serum sodium (Nas) levels less than 135 mmol/L.1 Hyponatraemia is the most common electrolyte disorder among elderly patients and is associated with increased mortality rates and longer hospital stays.2–4 The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a frequent cause of hyponatraemia in […]

Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – clinical endpoints and next steps

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 1st 2023

CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. We caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the primary and secondary endpoints and how well they were achieved, and the next steps in the clinical development of CM-101.

The abstract entitled ‘Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.

Questions:

  1. What were the primary and secondary endpoints and how well were they achieved? (0:14)
  2. What will be the next steps in the clinical development of CM-101? (4:41)

Disclosures: Rifaat Safadi is a consultant for Chemomab.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.

Filmed in coverage of EASL 2023

Access further content on liver disorders

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup